DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Long-Term Outcomes of Alternative Brachytherapy Techniques for Early Prostate Cancer

Conditions: Prostate Cancer

Interventions: Radiation: brachytherapy

First Posted Date: 2008-05-21

Last Posted Date: 2010-04-28

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 414

Registration Number: NCT00681694

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States

Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma

Not Applicable

Completed

Conditions: Low Grade Gliomas

Interventions: Radiation: Proton Radiation Therapy

First Posted Date: 2008-05-21

Last Posted Date: 2017-03-07

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 20

Registration Number: NCT00681473

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

Completed

Conditions: Nervous System Diseases
Amyotrophic Lateral Sclerosis
Lou Gehrig's Disease
Primary Lateral Sclerosis
Hereditary Spastic Paraparesis

Interventions: Other: No intervention

First Posted Date: 2008-05-14

Last Posted Date: 2016-06-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 475

Registration Number: NCT00677768

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of California Irvine, Orange, California, United States

and more 27 locations

Effects of Testosterone in Women With Depression

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Testosterone

First Posted Date: 2008-05-13

Last Posted Date: 2012-11-30

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 9

Registration Number: NCT00676676

Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis

Phase 2

Completed

Conditions: Nephrogenic Systemic Fibrosis

Interventions: Drug: Imatinib mesylate

First Posted Date: 2008-05-13

Last Posted Date: 2017-05-19

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 12

Registration Number: NCT00677092

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

Phase 2

Completed

Conditions: Abdominal Obesity
Growth Hormone Deficiency

Interventions: Drug: Growth hormone releasing hormone (GHRH) 1-44
Drug: Placebo

First Posted Date: 2008-05-09

Last Posted Date: 2017-12-13

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 60

Registration Number: NCT00675506

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Pancreatic Stent to Prevent Leak After Distal Pancreatectomy

Not Applicable

Withdrawn

Conditions: Pancreatic Surgery
Pancreatic Duct Stenting
Pancreatic Cancer
Distal Pancreatectomy
Pancreatic Diseases
Pancreatic Cyst
Pancreatic Ducts

Interventions: Procedure: Pancreatic duct stenting

First Posted Date: 2008-05-05

Last Posted Date: 2013-06-11

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT00671463

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung's Disease

Phase 1

Conditions: Chronic Constipation
Hirschsprung's Disease

First Posted Date: 2008-05-05

Last Posted Date: 2008-05-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 50

Registration Number: NCT00671684

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

Phase 1

Terminated

Conditions: Gastric Adenocarcinoma
Esophageal Adenocarcinoma

Interventions: Drug: panitumumab, epirubicin, oxaliplatin, xeloda

First Posted Date: 2008-04-28

Last Posted Date: 2014-07-04

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 17

Registration Number: NCT00667420

Locations: 🇺🇸
DFCI, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking

Not Applicable

Completed

Conditions: Tobacco Use Disorder

First Posted Date: 2008-04-22

Last Posted Date: 2013-12-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3000

Registration Number: NCT00664261

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy